Unlock instant, AI-driven research and patent intelligence for your innovation.
3-substituted coumarin derivatives and uses thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of coumarins and derivatives, which is applied in the field of medicine and can solve problems such as unsatisfactory drug efficacy
Inactive Publication Date: 2016-01-13
ZHEJIANG UNIV +1
View PDF1 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
The CB2 agonist GW842166X reported by GSK has completed three clinical phase II studies as an analgesicdrug, but the drug effect is not satisfactory (Giblin, G.M.P.; etal. Discovery of 2-[(2,4-Dichlorophenyl)amino]-N- CB2 The agonist S-777469 has also completed clinical phase II studies as a candidate drug for the treatment of atopic dermatitis (Odan, M., et al., Discovery of S-777469: anorally available CB2 agonist as an antipruriticagent.Bioorg.Med.Chem.Lett.,2012,22,2803-2806)
At present, the research on CB2 selective ligands is mostly concentrated in the preclinical stage and clinical research stage, and there is no marketed drug
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0088] a) Preparation of 3-ethoxy-2-hydroxybenzaldehyde 1a
[0089] 60% sodiumhydride (12.50mmol, 500mg) was suspended in 12.5mL of anhydrous DMSO, 2,3-dihydroxybenzaldehyde (5.00mmol, 690.6mg) was dropped into 2.5mL of anhydrous DMSO, and added after 1 hour at room temperatureBromoethane (5.00mmol, 544.9mg). React at room temperature for 24 hours. It was quenched with water and extracted with dichloromethane. The aqueous layer was adjusted to PH=2 with 1M HCl and then extracted with dichloromethane. The organic layers were combined and washed with saturated brine, dried over anhydrousmagnesiumsulfate, and distilled under reduced pressure to obtain a crude product. After separation and purification by column chromatography, the elution condition is petroleumether: ethyl acetate=10:1~6:1, and 1a is obtained as a yellow solid 441.2mg, the yield is 53.1%, and the melting point is 65.3-66.8°C.
[0101] The preparation of compound CHA02 is the same as that of compound CHA01 in Example 1, except that 3-aminomethylpyridine (0.12mmol, 13.0mg) is used instead of benzylamine to obtain CHA02 as a yellow solid, 17.7mg, with a yield of 54.7%. Melting point 213.5-214.8°C.
[0104] The preparation of compound CHA03 is the same as that of compound CHA01 in Example 1, except that cyclohexylamine (0.12mmol, 11.9mg) is used instead of benzylamine to obtain CHA03 as a white solid 4.3mg, yield 13.7%, melting point 150.8- 151.6°C.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention provides a 3-substituted coumarin derivative and its pharmaceutically acceptable salt, solvate, hydrate or crystal form. The compound of the invention generally exhibits higher calcium flow activity and good selectivity to human cannabinoidreceptor CB2, and is a specific agonist or inverse agonist of the cannabinoidreceptor CB2. The compounds provided by the present invention are active ligands of the novel cannabinoid type II receptor CB2, and the compounds and their pharmaceutically acceptable salts, solvates, hydrates or crystal forms generally exhibit relatively high High calcium flux activity and good selectivity. The compound of the invention is a specific agonist or an inverse agonist of the cannabinoid receptor CB2, and can be used in the preparation of medicines for treating, preventing and inhibiting diseases mediated by the CB2 receptor. The general formula A of the derivative is as follows:.
Description
technical field [0001] The invention belongs to the technical field of medicine, relates to a class of 3-substituted coumarin CB2 active ligands, in particular to 3-substituted coumarin compounds and their pharmaceutically acceptable salts, solvates, hydrates or crystal forms in Use in the preparation of medicaments for the treatment of diseases mediated by the cannabinoid type II receptor CB2. Background technique [0002] As early as several centuries ago, people have realized that plantcannabis has medicinal effects such as pain relief, anti-vomiting, anti-convulsion, and anti-inflammation. Cannabinoids are also one of the earliest addictive substances recognized by humans. Studies have proved that there are at least two subtypes of cannabinoid receptors: CB1 receptors and CB2 receptors, both of which belong to the rhodopsin-like family of G protein-coupled receptors (GPCRs) and have a 7-segment α-helix transmembrane structure , its complete amino acid sequence has 44% ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
